Medical devices, healthcare technology and the business of care
PMA approval · P050023

TUPOS LV/ATX & KRONOS LV-T CRT-D & COROX OWT STEROID LV PACING LEAD

Biotronik, Inc. · Decision date Aug 10, 2006

MEDTECHLEDGER EXPLANATIONP050023

What did the FDA approve?

FDA approval P050023, dated August 10, 2006, covers the TUPOS LV/ATX CRT-D, KRONOS LV-T CRT-D, 505.U programmer software for the ICS 3000, A-K00.7.U programmer software for the EPR/TMS 1000PLUS, and COROX OTW steroid lead. The TUPOS LV/ATX and KRONOS LV-T devices are indicated for patients who meet four conditions: an ICD therapy indication, optimized and stable congestive heart failure drug therapy, symptomatic CHF with NYHA Class III/IV and LVEF at or below 35%, and intraventricular conduction delay with QRS duration of at least 130 ms.

The TUPOS LV/ATX adds an indication for patients who also have atrial tachyarrhythmias or are at risk of developing them. The COROX OTW steroid leads are intended for implantation via the coronary veins to provide long-term cardiac pacing with a compatible pulse generator. The statement reports the approved indications and intended use; it does not independently establish safety or clinical effectiveness.

FDA approval order statement

APPROVAL FOR THE TUPOS LV/ATX CRT-D, KRONOS LV-T CRT-D, 505.U PROGRAMMER SOFTWARE FOR THE ICS 3000, A-K00.7.U PROGRAMMER SOFTWARE FOR THE EPR/TMS 1000PLUS AND COROX OTW STEROID LEAD. THE TUPOS LV/ATX AND KRONOS LV-T CRT-DS ARE INDICATED FOR USE IN PATIENTS WITH ALL OF THE FOLLOWING CONDITIONS: 1) INDICATED FOR ICD THERAPY; 2) RECEIVING OPTIMIZED AND STABLE CONGESTIVE HEART FAILURE (CHF) DRUG THERAPY; 3) SYMPTOMATIC CHF (NYHA CLASS III/IV AND LVEF <=35%); AND 4) INTRAVENTRICULAR CONDUCTION DELAY (QRS DURATION >=130 MS). THE TUPOS LV/ATX IS ALSO INDICATED FOR PATIENTS WHO, IN ADDITION TO AN INDICATION FOR A CRT-D DEVICE, HAVE ATRIAL TACHYARRHYTHMIAS OR ARE AT RISK OF DEVELOPING ATRIAL TACHYARRHYTHMIAS. THE COROX OTW STEROID LEADS ARE INTENDED FOR IMPLANTATION VIA THE CORONARY VEINS TO PROVIDE LONG TERM CARDIAC PACING WHEN USED IN CONJUNCTION WITH A COMPATIBLE PULSE GENERATOR.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Aug 10, 2006

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P050023
Regulatory pathway
Premarket approval application
Product code
MRM
Decision code
APPR
Decision date
Aug 10, 2006
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: DEFIBRILLATOR, IMPLANTABLE, DUAL-CHAMBER.

Product code
MRM
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P050023 received

    Application receipt date recorded by FDA.

  2. P050023 · FDA decision

    APPR

  3. P050023/S211 · Related supplement

    PSW 2601.U, NEO 2601.U, Acticor Sky HF-T, Rivacor Sky HF-T, Rivacor Rise HF-T, Rivacor Aura HF-T, Acticor Sky HF-T QP, R

  4. P050023/S204 · Related supplement

    Ilivia 7 VR-T DX 404624; Intica 7 VR-T DX 404633; Intica 5 VR-T DX 404688; Ilivia 7 VR-T 404625; Intica 7 VR-T 404634; I

  5. P050023/S214 · Related supplement

    Acticor Sky HF-T, Rivacor Sky HF-T, Rivacor Rise HF-T, Rivacor Aura HF-T, Acticor Sky HF-T QP, Rivacor Sky HF-T QP, Riva

  6. P050023/S213 · Related supplement

    Acticor Sky HF-T 481986; Rivacor Sky HF-T 481991; Rivacor Rise HF-T 482017; Rivacor Aura HF-T 482013; Acticor Sky HF-T Q

  7. P050023/S215 · Related supplement

    Ilivia 7 VR-T DX DF-1 ProMRI Ilivia 7 VR-T DF-1 ProMRI Ilivia 7 VR-T DF4 ProMRI Intica 7 VR-T DX DF-1 ProMRI Intica 7 VR

  8. P050023/S216 · Related supplement

    Ilivia 7 VRT DX, Intica 7 VRT DX, Intica 5 VRT DX, Ilivia 7 VRT, Intica 7 VRT, Intica 5 VRT, Inlexa 7 VRT, Inlexa 7 VRT

Timeline entries are records held by MedtechLedger for P050023. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P050023

Explore the linked device profile

Other records with product code MRM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records